Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "Neuroactive steroid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.
Neuroactive steroids, compositions, and uses thereof
InactiveUS20160022701A1Increase and decrease endogenous activityImprove bioavailabilityOrganic active ingredientsNervous disorderMedicineNeuroactive steroid
Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and / or evaluating the sample for an alteration in the level S24(S)-hydroxycholesterol compared to a reference standard.
Owner:SAGE THERAPEUTICS
19-NOR neuroactive steroids and methods of use thereof
ActiveUS9365611B2Eliminate potential for oxidationImprove bioavailabilityOrganic active ingredientsSenses disorderWithdrawal syndromeSubstance abuser
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, and status epilepticus.
Owner:SAGE THERAPEUTICS
Neuroactive steroids and methods of use thereof
InactiveUS20160031930A1Maintain good propertiesGood metabolic stabilityOrganic active ingredientsSenses disorderNeuroactive steroidPharmacology
(3alpha,3beta)-disubstituted 17beta steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
Owner:SAGE THERAPEUTICS
19-nor neuroactive steroids and methods of use thereof
ActiveUS20160083418A1Eliminate potential for oxidationInhibit metabolismOrganic active ingredientsSenses disorderSubstance abuserWithdrawal syndrome
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.
Owner:SAGE THERAPEUTICS
19-nor neuroactive steroids and methods of use thereof
InactiveUS20160068563A1Eliminate potential for oxidationImprove bioavailabilityNervous disorderEstrane derivativesSubstance abuserWithdrawal syndrome
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, status epilepticus.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
InactiveUS20160229887A1Useful in therapyReduces avoids symptom causeOrganic active ingredientsSenses disorderSedationNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
InactiveUS20170233433A1Reduces avoids symptom causeGood curative effectOrganic active ingredientsNervous disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
ActiveUS10246482B2Reduces avoids symptom causeGood curative effectKetal steroidsSubstance abuserWithdrawal syndrome
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
InactiveUS20190177358A1Reduces avoids symptom causeGood curative effectOrganic active ingredientsNervous disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
ActiveUS20170240589A1Reduces avoids symptom causeGood curative effectOrganic active ingredientsNervous disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein (II), A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Owner:SAGE THERAPEUTICS
Neuroactive steroids and methods of use thereof
InactiveUS20170305960A1Excellent propertyGood metabolic stabilityOrganic active ingredientsSenses disorderNeuroactive steroidStereochemistry
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.
Owner:SAGE THERAPEUTICS
19-nor neuroactive steroids and methods of use thereof
ActiveUS20170233432A1Eliminate potential for oxidationImprove bioavailabilityNervous disorderEstrane derivativesWithdrawal syndromeSubstance abuser
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I):and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, tinnitus, status epilepticus.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
ActiveUS10329320B2Reduces avoids symptom causeGood curative effectOrganic active ingredientsNervous disorderSedationNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Multiple-component pharmaceutical formulations and methods for their use in treating neuropathology and neurodegeneration caused by traumatic injury
Novel two-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as pregabalin. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat.Owner:SAPNA LIFE SCI
Neuroactive steroids, compositions, and uses thereof
ActiveUS20180215779A1Reduces avoids symptom causeGood curative effectOrganic active ingredientsNervous disorderSedationNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
ActiveUS20170247406A1Reduces avoids symptom causeGood curative effectKetal steroidsSubstance abuserWithdrawal syndrome
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
PendingUS20180179247A1Eliminate potential for oxidationInhibit metabolismOrganic active ingredientsNervous disorderWithdrawal syndromeSubstance abuse disorder
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS
Neuroactive steroid compositions and methods of use therefor
InactiveUS20130210783A1Improve cognitive functionPromote more developedBiocideOrganic active ingredientsDiseaseSchizo-affective type
Provided are methods for ameliorating a symptom of a neuropsychiatric disorder. Also provided are methods for ameliorating at least one symptom resulting from tobacco cessation; and for ameliorating a symptom of Alzheimer's disease or other cognitive disorder; of schizophrenia, schizoaffective disorder, or other psychotic disorder; of a depressive disorder; of bipolar disorder; of post-traumatic stress disorder or other anxiety disorder; of a pain disorder; or of traumatic brain injury. Also provided are methods for ameliorating a sleep disorder; for improving cognitive functioning; for predicting a predisposition to suicide, suicidal ideation, and / or suicidal behavior; and for ameliorating a neurodegenerative disorder. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a neuroactive steroid composition, pharmaceutically acceptable salts thereof, derivatives thereof, or combinations thereof.
Owner:DUKE UNIV
Neuroactive steroids, compositions, and uses thereof
InactiveUS20160152658A1Convenient treatmentGood curative effectOrganic active ingredientsNervous disorderSedationNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Owner:SAGE THERAPEUTICS
General anesthetics that are not neurotoxic
The present application discloses the unexpected result that a neuroactive steroid such as B260 can act as a general anesthetic and that it has no neurotoxic side effects such as impairing brain development.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Two-component formulations, methods and procedures to prevent or reduce trauma-induced neuropathology and neurodegeneration
Novel two-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, and at least one anti-epileptic or anticonvulsant, such as gabapentin. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat.Owner:SAPNA LIFE SCI
Anaesthetic formulation
The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host / guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.
Owner:DRAWBRIDGE PHARMA
Compositions and methods for treating CNS disorders
ActiveUS20170319695A1Reduces avoids symptom causeGood curative effectOrganic active ingredientsSenses disorderDiseaseNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I):
or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
ActiveUS20170342102A1Convenient treatmentGood curative effectOrganic active ingredientsSenses disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
ActiveUS20200024301A1Reduces and avoids symptom and causeGood curative effectOrganic active ingredientsNervous disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (I); or a pharmaceutically acceptable salt thereof, wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Neuroactive steroids and their methods of use
InactiveUS20200281943A1Reduction from baselineImprove bioavailabilityOrganic active ingredientsNervous disorderDiseaseEssential tremor
This disclosure relates to Compound (I), pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor; depression; and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.
Owner:SAGE THERAPEUTICS
Compositions and methods for treating CNS disorders
ActiveUS10774108B2Reduces avoids symptom causeGood curative effectOrganic active ingredientsSenses disorderDiseaseSedation
Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
Neuroactive steroids, compositions, and uses thereof
ActiveUS11498940B2Reduces avoids symptom causeGood curative effectOrganic active ingredientsSenses disorderSedationNeuroactive steroid
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS
3alpha, 5beta-neuroactive steroids for the treatment of epilepsy and seizure diseases
PendingUS20220162257A1Suppressed convulsive seizuresReduce morbidityOrganic active ingredientsNervous disorderConvulsionDisease
3α5β-steroid compounds of general formula I is disclosed. These compounds are useful in the treatment of epilepsy or comorbidities associated with epilepsy or conditions associated with convulsions, such as seizures associated with hypoxia, seizures associated with traumatic brain damage, seizures associated with intoxication, pathological changes caused by hyperexcitation, or in treatment of conditions accompanying epilepsy, such as affective disorders, depression, post-traumatic stress disorder (PTSD) and stress-related diseases, anxiety, schizophrenia and psychotic disorders, related ischemic CNS damage, neurodegenerative changes and disorders, multiple sclerosis. The compounds of general formula I also show age-specific efficacy.
Owner:INST OF ORGANIC CHEM & BIOCHEMISTRY OF THE ACAD OF SCI OF THE CZECH REPUBLIC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap